Insulet Artificial Pancreas Free-Living IDE3

What is the purpose of this trial?

Subjects will undergo a 7±1 day outpatient, standard therapy phase during which sensor and insulin data will be collected. Subjects or their caregivers will manage their diabetes at home per their usual routine using the study CGM and remain on current MDI or pump therapy. This will be followed by a 5-day/4-night, hybrid closed-loop phase conducted in a supervised hotel/rental house setting.


Participation Guidelines

Ages: 6 - 65 years

Gender: Both


Insulet Corporation

Start Date: 08/01/2017

End Date: 12/31/2017

Last Updated: 02/22/2018

Study HIC#: 2000021293

Get Involved

For more information about this study, contact:
Lori Carria
+1 203-737-3595
lori.carria@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image

Investigators

Jennifer Sherr

Principal Investigator

Sub-Investigators